Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidase M20 domain containing 2 (PM20D2) is a metalloenzyme in the metallopeptidase 20 family that acts as a “metabolite repair” enzyme, especially in tissues with active carnosine synthase such as muscle, heart, and brain. Its main role is to hydrolyze noncanonical dipeptides—particularly those derived from β-alanine and γ-aminobutyrate linked to basic amino acids (lysine, ornithine, arginine)—which are produced as byproducts when carnosine synthase uses alternative substrates. PM20D2 thereby prevents their accumulation, ensuring the synthesis of physiologically relevant dipeptides like carnosine and homocarnosine, and contributes to metabolic regulation and dipeptide homeostasis. Human PM20D2 displays 100–200 fold lower enzymatic activity compared to mouse PM20D2[1][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidase M20 domain containing 2 (PM20D2).